Search

Kidney cancers that metastasize to the pancreas have a fundamentally different biology from those that metastasize elsewhere

Researchers at UT Southwestern Medical Center have discovered how a hormone interacts with a receptor on the surface of immune cells to shield cancer cells from the body’s natural defenses. The findings, published in Nature Immunology, could lead to new immunotherapy approaches for treating cancer

Less than three weeks after getting on an organ transplant list for HIV-positive patients, John Welch got the call. A liver was available from a deceased donor, and it was an excellent match.

Tripling the standard dose of semaglutide, a popular drug prescribed to treat obesity, led to significantly greater weight loss and associated metabolic benefits without increased risk of serious side effects, a multicenter clinical trial led by a UT Southwestern Medical Center researcher shows.

A study from UT Southwestern researchers sheds new light on how the bug that’s the No. 1 cause of bacterial diarrhea finds its way through the human gut.

In Memoriam: David J. Mangelsdorf, Ph.D., pioneer in orphan nuclear receptor research and Chair of Pharmacology Published on: August 09, 2025 • By: Newsroom Share Share on Facebook Share on Twitter Share on LinkedIn Email this page Print this page DALLAS – Aug. 9, 2025 – David J. Mangelsdorf, Ph.D., Chair and Professor of Pharmacology at UT Southwestern Medical Center, a visionary scientist who pioneered the once-obscure realm of orphan nuclear receptors (a class of proteins involved in gene

Traci d’Auguste, M.B.A., M.S.H.A., who has more than two decades of leadership experience in academic medicine, is the new Vice President and Chief Executive Officer of UT Southwestern Medical Center’s William P. Clements Jr. University Hospital (CUH), effective today.

Cancer cells avoid an immune system attack after radiation by commandeering a cell signaling pathway that helps dying cells avoid triggering an immune response

Immunotherapy drugs that target a protein called programmed death ligand 1 (PD-L1) on the surface of cancer cells have quickly become a mainstay to treat many forms of cancer, often with dramatic results.

If not teamed with psychological, social, and emotional support, cancer news can negatively impact young patients’ emerging developmental needs and perspectives.